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BMI; body mass index  
CV; coefficient of variation 
DXA; dual-energy X-ray absorptiometry 
hs-CRP; high-sensitivity C-reactive protein  
IP; Intestinal permeability  
L-R; lactulose-rhamnose  
LPS; lipopolysaccharide  
VAT; visceral adipose tissue 
WC; waist circumference  























The association between intestinal permeability (IP) and body composition remains 
unclear. The gold standard differential sugar-absorption test is arduous to complete, 
with zonulin being increasingly used as an independent biomarker of IP. This pilot 
study aimed to explore the association between small IP, zonulin concentrations and 
body composition in healthy adults. The urinary lactulose-rhamnose ratio was used 
to measure small IP. Serum zonulin, lipopolysaccharide (LPS) and high-sensitivity C-
reactive protein (hs-CRP) were analyzed in serum. Body c mposition was measured 
using dual-energy X-ray absorptiometry and anthropometric measurements were 
collected. In total, 34 participants were included (12 males, median age 28 years, 
body mass index 24kg/m2, waist circumference 77cm). No correlation was observed 
between the lactulose-rhamnose ratio and zonulin (r -0.016, p 0.929). The lactulose-
rhamnose ratio displayed a strong positive correlation with LPS (n 22, r 0.536, p 
0.018) but did not correlate with body composition measures. Conversely, zonulin 
displayed a moderate positive correlation with waist circumference (r 0.437, p 0.042) 
in female participants and hs-CRP (r 0.485, p 0.004) in all participants. These 
findings raise important c nsiderations for the measurement of small IP, warranting 
exploration in larger powered studies that address the limitations of the present 
study. 
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The importance of intestinal barrier homeostasis is being increasingly recognized in 
the scientific literature [1 2]. The differential sugar-absorption test is considered the 
current non-invasive in vivo gold standard method of measuring intestinal 
permeability (IP). Non-digestible sugars that provide a measure of transcellular (e.g. 
L-rhamnose) and paracellular (e.g. lactulose) permeability are ingested and 
subsequently measured in urine. The higher the ratio of paracellular to transcellular 
permeability, the more severe the IP [3]. Increased IP, a reflection of impaired 
intestinal barrier function, has been associated with endotoxemia and inflammation 
in clinical populations [1]. There is emerging evidence to suggest that IP may be 
altered in obesity in otherwise healthy populations [4 5].  
 
The association between obesity and increased IP was first elucidated in animal 
studies [4]. One of the first studies to explore this relationship in healthy adults found 
no differences in the lactulose-mannitol (a measure of small IP) and lactulose-
sucralose (a measure of colonic permeability) ratios in 13 obese and 11 control 
participants [6]. Subsequent studies completed in healthy female adult participants 
have reported a positive association between small and colonic IP and waist 
circumference (WC) [7 8], as well as colonic IP and visceral adiposity [7]. These 
findings suggest that central and in particular visceral adiposity, independent of 
weight status, may contribute to increased IP [7 8]. This may be explained in part by 
the association between visceral adipose tissue (VAT) and inflammation, irrespective 














weight and abdominal adiposity are associated with inflammation, insulin resistance 
and liver steatosis [4 10].  
 
Although the differential sugar-absorption test is widely used to measure IP, it is 
onerous and expensive to complete. Zonulin, more recently identified as 
prehaptoglobin-2, is a ~47-kDa protein that is capable of modulating intercellular 
tight junctions in the small intestine, with increased concentrations in blood indicative 
of increased small IP [11 12]. Zonulin is being used independently of the differential 
sugar-absorption test as a measure of small IP, owing to the ease of analyzing 
concentrations of zonulin in blood.  
 
However, limited studies have explored the association between zonulin 
concentrations and the differential sugar-absorption test [13]. Furthermore, zonulin 
concentrations are associated with obesity in healthy adults and have also been 
found to be higher in individuals with higher WCs, waist: hip ratios, fat mass and total 
fat percentage [14-16]. To our knowledge limited studies have explored the 
association between small IP, zonulin concentrations and body composition 
measures in healthy populations. The hypothesis for this prospective pilot study was 
that small IP would display a positive and significant association with zonulin 
concentrations and measures of abdominal adiposity. The study aimed to explore 
the relationship between small IP, zonulin and body composition. Specifically, the 
objectives of the study were twofold; (1) to explore whether small IP measured using 
the differential sugar-absorption test is associated with zonulin concentrations and 
(2) to explore the association between small IP, zonulin concentrations and body 














understanding of the measurement of small IP using gold standard methods and its 
relationship with body composition measures and may assist in informing the 
management of increased small IP and/or abdominal adiposity in healthy adults in 
future.  
 
2. Methods and materials 
 
This prospective pilot study was conducted at La Trobe University in Melbourne, 
Australia. The study was approved by the La Trobe University Human Ethics 
Committee and written consent was obtained from all participants prior to study 
commencement. The study was not registered.  
 
Adults aged 18 years or older with no current or past history of diabetes, heart 
disease and gastrointestinal conditions (including gastrointestinal intolerances) were 
invited to take part in the study. Adults who were pregnant or those that had taken 
antibiotics or nonsteroidal anti-inflammatory drugs within the fortnight prior to study 
commencement were excluded. Screening processes were conducted via email 
and/or telephone, with eligibility reassessed prior to obtaining written consent at the 
first study appointment. The study was advertised on social media platforms and 
study flyers were distributed throughout the La Trobe University Bundoora campus, 
General Practitioner clinics in the City of Darebin and The Alfred Hospital, 
















Participants meeting the eligibility criteria and consenting to take part in the research 
study attended La Trobe University, Bundoora campus on three separate occasions 
for study appointments (Figure 1).  
 
2.1 Demographics and health information  
 
Participant demographics and health information, including current and past medical 
history, smoking status, alcohol intake, weekly physical activity (minutes per week of 
total, moderate [e.g. walking] and vigorous [e.g. jogging]), the use of medication and 
nutrition supplements were collected using a questionnaire at the initial appointment. 
Smoking and alcohol intake were assessed using questions from the 2013 National 
Drug Strategy Household Survey [17], while physical activity was assessed using 
questions from the Active Australia Survey [18]. 
 
2.2 Intestinal permeability measurements  
 
Small IP was measured using 0.5 g L-rhamnose and 1 g of lactulose mixed together 
and dissolved in potable water. This pilot study formed part of a research project 
measuring segmental IP, however this manuscript reports the results relating to 
small IP only as measured using the lactulose-rhamnose (L-R) ratio as the zonulin 
system is not operative in the large intestine [19 20]. The sugar dosages used were 
based on the novel and sensitive analytical method published by van Wijck and 















As the optimal sampling time for IP tests is debatable and dependent on individual 
participants’ intestinal transit times [22 23], the percentage urinary recovery of each 
sugar was calculated in 24-hour urine samples in order to capture complete urinary 
sugar excretion along the gastrointestinal tract. 
 
Prior to commencing urine collections, participants were asked to empty their 
bladders. A baseline non-fasted 24-hour urine collection was conducted to determine 
the concentrations of sugars in urine samples prior to the administration of the sugar 
solution. Following completion and return of the baseline urine collection, participants 
consumed a 50 mL solution containing the sugar probes dissolved in potable water. 
Participants collected urine for a subsequent 24-hour period, referred to as the ‘test’ 
collection.  
 
Once returned, the weight of the 24-hour urine collections were recorded and 
participants were asked whether all urine produced during the 24-hour collection 
period was collected, including reasons for incomplete collections. The weight of 1 
ml of urine was determined in triplicate (3 x 1 ml aliquots) for each participant 24-
hour urine sample to allow for conversion of urine collection weight (kg) to volume 
(L). Samples were vortexed to achieve a homogeneous solution and aliquots were 
stored at -80°C until analysis.  
   
Urinary concentrations of sugars in baseline and test samples were analyzed using 
gas chromatography- mass spectrometry. Samples were extracted and analyzed by 
staff at Metabolomics Australia at The University of Melbourne, a National 














Pty Ltd. In brief, a 20-microliter aliquot of homogenised urine sample was treated 
with 20 µL of urease (1 mg of urease [V7752-VL]) and dissolved in 1 ml of Milli-Q 
water) following 15 minutes incubation at 30°C with a mixing speed of 950 rpm. 
Subsequently, 150 µL of 100% cold methanol containing 1% (v/v) 13C6 sorbitol was 
added to the sample and vortexed before being incubated on ice for 10 minutes. The 
sample was then centrifuged for 15 minutes at 13,000 rpm (4°C). A 50 µL aliquot of 
supernatant was dried down in glass insert in vacuo using a Rotational Vacuum 
Concentrator (RVC 2-33 CD plus, John Morris Scientific, Pty Ltd) set at ambient 
temperature, prior to the derivatisation. The dried sample was prepared in 20 µL of 
30 mgmL-1 methoxyamine hydrochloride in pyridine followed by two hours at 37°C 
with mixing at 500 rpm. The sample was then derivatised with 20 µL of N,O-bis 
(Trimethylsilyl) trifluoroacetamide with trimethylchlorosilane (BSTFA with 1% TMCS, 
Thermo Scientific) for 30 minutes at 37°C. The sample was then left for 1 h before 1 
µL was injected onto the gas chromatography column using a hot needle technique. 
Sugar concentrations present in each sample were quantified by acquiring 9 points 
calibration series: 160, 80, 40, 20, 10, 5, 2.2, 1.25, 0.625 µM containing L-rhamnose 
and lactulose. Data was processed using Agilent MassHunter Quantitative Analysis 
software (B.07.00). 
 
The concentrations of sugars in baseline and test urine samples were analyzed in a 
non-fasted state using the method described above and reported in μmol/L. 
Participants were advised to adhere to their normal diet during the study period.   
 
When calculating the (1) urinary excretion of each sugar and (2) urinary recovery of 














used. Urinary excretion of sugar (μmol) = concentration of sugar in urine (μmol/L) x 
total 24-hour volume of urine (L). Percent urinary recovery of sugar = (urinary 
excretion of sugar [μmol]/ quantity of sugar ingested [μmol]) x 100. 
 
Baseline sugar concentrations were subtracted from test sample concentrations to 
increase IP test accuracy [21]. Values were excluded from analysis if sugar 
concentrations were higher in baseline samples in comparison to test samples. The 
L-R ratio was used to measure small IP, as both L-rhamnose and lactulose undergo 
degradation by bacteria in the large intestine [21 24]. The percentage recovery of L-
rhamnose was used to measure small intestine transcellular permeability, while the 
percentage recovery of lactulose was used as a measure of small intestine 
paracellular permeability. 
 
2.3 Zonulin measurements 
 
Blood samples were collected at the first study appointment in a non-fasted state. 
Serum zonulin concentrations were analyzed in duplicate using a 96 well plate 
ELISA kit (K5601, Immundiagnostik AG®, Bensheim, Germany), with the 
absorbance measured at 450 nm. The lower limit of detection for the kit was 0.225 
ng/mL. The intra- and interassay coefficient of variation (CV) for the ELISA kit was 
between 3.4-6.0% and 13.3-13.6%, respectively. Based on information included in 
the analysis kit manual, the median value of zonulin in the serum of 40 healthy 
individuals included in Immundiagnostik studies was reported to be 34 ng/mL (±14 















2.4 Body composition measures  
 
Anthropometric measurements were completed at the first study appointment. 
Participants were asked to empty their bladders, remove their shoes and any heavy 
items from their pockets prior to the completion of measurements. Measurements 
were completed in duplicate by the same researcher, with the mean of two measures 
recorded to the nearest tenth of a centimeter/ kilogram (0.1 cm/ 0.1 kg). 
Anthropometric measurements included weight, height, waist and hip circumference. 
BMI, WC and waist-hip ratio were calculated and cut-offs were categorized in 
accordance to World Health Organization (WHO) classifications [25 26]. 
 
Body composition was measured using the Hologic Discovery W QDR 4500A fan 
beam Dual-energy X-ray absorptiometry (DXA) device (Hologic, Inc., Bedford, MA). 
Prior to each scan, calibration was performed using a spine phantom, according to 
the manufacturer instructions. The DXA measurements included total body fat (%), 
trunk fat (%) and VAT (cm2). VAT was estimated by the DXA analysis software 
based on a patented method developed by Hologic [27]. 
2.5 Analyses of C-reactive protein and lipopolysaccharide   
 
High-sensitivity C-reactive protein (hs-CRP) and lipopolysaccharide (LPS) were 
measured in blood samples as markers of inflammation and bacterial translocation, 
respectively.  The analysis of hs-CRP in serum samples was performed by Dorevitch 
Pathology using particle enhanced turbidimetric assay. The lower detection limit for 
the assay was 0.1 mg/L and the intra- and interassay CV was 0.6-1.3% and 2.2-














[28 29]. Concentrations between ≥3 and ≤10 mg/L were considered to be indicative 
of low-grade inflammation, whilst concentrations of hs-CRP >10mg/L were 
considered to be reflective of an acute infection [28 29].  
 
The concentration of LPS was analyzed in a subset of participants. Serum samples 
were analyzed in duplicate using a 96 well plate ELISA kit (Abbexa®, Cambridge, 
UK), with the absorbance measured at 450nm. The range of detection for the kit was 
0.015-1 EU/mL, with a sensitivity of <0.0078 EU/mL. The intra- and interassay CV 
for the ELISA kit was reported as ≤4.3% and ≤5.5%, respectively.  
 
2.6 Sample size 
 
This pilot study formed part of a research project determining the utility of a sensitive 
multi-sugar test in measuring segmental IP in healthy participants in a non-fasted 
state. As differences in the dosage of sugar probes, urine sampling times and 
analysis techniques can all influence IP measurements, a sample size calculation 
was not performed for the broader research question and aims explored in this paper 
due to lack of data available in this area utilizing comparable methods. 
 
2.7 Statistical analyses 
 
All statistical analyses were conducted using IBM® SPSS® Statistics for Windows, 
Version 25.0 (Armonk, NY: IBM Corp). Normality tests were first performed to 
determine the distribution of data points of interest using the Shapiro-Wilk test. 














describe normally distributed data, whilst medians and interquartile range (IQR) were 
used to describe data that violated the assumption of normality. For independent 
variables, the Independent-Samples t Test was used for normally distributed data 
and the Mann-Whitney U test was used for data that was not normally distributed. 
Correlation analyses was used to explore relationships between small IP, zonulin 
and body composition parameters. The Pearson correlation coefficient was used for 
normally distributed data, whilst a Spearman Rho Test was used to explore 
associations for variables that were not normally distributed. A two-tailed p-value 




During the recruitment period, 35 participants met the eligibility criteria and were 
included in the study. One participant did not return urine samples, leaving 34 
participants with IP results (Figure 2). Participant characteristics are displayed in 
Table 1. Participants had a median age of 28 (IQR 17) years and were 
predominantly female (64.7%). The majority of participants were non-smokers 
(91.2%) and consumed alcohol between 1-2 days weekly (29.4%) or 1-3 days a 
month (29.4%). Six (17.6%) of the 34 participants listed a past medical history that 
has been linked to increased IP in the literature, such as asthma, dermatitis and 
depression/anxiety but were not taking prescription medication related to these 
conditions [30-32]. All of the remaining participants either had no past medical 
history or unrelated history such as orthopedic surgeries completed several years 
prior to participation. Six (17.6%) participants were taking regular medications 














male pattern hair loss (n = 1). Three participants (8.8%) had taken antibiotics within 
two months of participation but not within the two-week timeframe outlined as part of 
the eligibility criteria. Nutrition supplements, including nutrition ergogenic aids, were 
consumed by 19 (55.9%) participants. The most commonly consumed supplements 
included fish oil, multivitamins, individual vitamin and mineral supplements and 
nutrition ergogenic aids such as pre-workout, protein, amino acid and creatine 
supplements. No differences were observed in age between male and female 
participants. However, weekly physical activity and body composition measures, 
excluding hip circumference, differed significantly between males and females (Table 
1). The L-R ratio and zonulin concentrations did not differ according to the patient 
characteristics mentioned above (data not shown).  
 
3.1 Intestinal permeability measurements 
 
The median urinary volume for baseline and test collections was 2.0L (IQR 1.3L) and 
2.3L (IQR 1.3L), respectively. For baseline collections, 24 (71%) participants 
reported complete urine collections, with ten participants (29%) reporting incomplete 
collections during the measurement period. For test collections, 19 (56%) 
participants reported complete urine collections, with 15 (44%) reporting incomplete 
collections during the measurement period. The most common reasons for 
incomplete collections were forgetting to collect urine samples overnight and omitting 
to collect samples at social outings. There were no significant differences in the L-R 
ratio between participants who reported complete versus incomplete collections 
(median L-R ratio 0.032 [0.018] versus 0.025 [0.024], respectively, p 0.321), with the 















Concentrations of sugars prior to the consumption of the sugar solution were 
analyzed in 24-hour baseline urine collections. L-rhamnose and lactulose were 
detected in 18 (53%) and 16 (47%) baseline urine collections, respectively. 
Concentrations of sugars in baseline 24-hour urine collections were compared with 
concentrations in test 24-hour urine collections in order to determine if IP 
measurements could be reliably interpreted in a non-fasted state. The concentration 
of L-rhamnose increased substantially following consumption of the sugar solution 
[4.8 (8.1) and 139.3 (147.0) μmol/L and interquartile range, respectively for baseline 
and urine collection p <0.001], with no overlap between baseline and test 
concentrations at the participant level. Although the group median concentration of 
lactulose in baseline samples increased significantly following consumption of the 
sugar solution from 0 to 12 μmol/L (p <0.001) [values 0.0 (8.3) and 11.9 (6.2) μmol/L 
and interquartile range, respectively for baseline and urine collection p <0.001], the 
concentration of lactulose in one participant’s baseline sample exceeded the 
concentration in the test sample. For this reason, the L-R ratio has been reported in 
33 participants (Table 2).  
 
3.2 Intestinal permeability and zonulin measurements 
 
Zonulin concentrations are displayed in Table 2. No correlation was observed 
between zonulin concentrations and the L-R ratio (r -0.016, p 0.929), the percentage 
recovery of L-rhamnose (r -0.298, p 0.087) or the percentage recovery of lactulose (r 















3.3 Intestinal permeability, zonulin, hs-CRP and LPS 
 
LPS concentrations were measured in a subgroup of participants (n = 20) (Table 2). 
A strong positive correlation was observed between LPS concentrations and the L-R 
ratio (r 0.536, p 0.018). No correlation was observed between LPS and zonulin 
concentrations (r 0.047, p 0.845).  
 
Median hs-CRP concentrations for the group were 0.32 (IQR 0.86) mg/L, with three 
participants considered to have an elevated hs-CRP concentration indicative of low-
grade inflammation and one participant with an elevated hs-CRP concentration 
indicative of acute elevation (Table 2). Participants with elevated hs-CRP 
concentrations did not differ from remaining participants in characteristics and there 
were no indicators as to why hs-CRP concentrations were elevated in these 
participants. The L-R ratio did not correlate with hs-CRP concentrations (r 0.039, p 
0.831). Similarly, the L-R ratio was not higher in participants with elevated versus 
normal hs-CRP concentrations (0.044 versus 0.028, respectively, p 0.184). In 
contrast, zonulin concentrations displayed a significant and moderate positive 
correlation with hs-CRP concentrations (r 0.485, p 0.004). Similarly, mean zonulin 
concentrations were significantly higher in participants with elevated (n = 4) versus 
normal (n = 30) hs-CRP concentrations despite the small participant numbers (60.2 
versus 43.7 ng/mL, respectively, p <0.001). No correlation was observed between 
hs-CRP and LPS concentrations (r -0.246, p 0.297).  
 















Body composition measures are presented in Table 1. The median BMI of 
participants was 23.2 (IQR 5.6) kg/m2. Based on the WHO BMI classifications, 22 
participants (65%) had a BMI within the healthy range, eight participants (24%) were 
classified as overweight and four participants (12%) were classified as obese. Of the 
12 participants (35%) classified as either overweight or obese, five participants 
(15%, n = 1 male, n = 4 females) had a WC indicative of “substantial risk” (>102 cm 
for males and >88 cm for females) [25]. Similarly, three participants (9%, n = 1 male, 
n = 2 females) had a waist: hip ratio indicative of “substantial increased risk” based 
on WHO guideline classifications (≥0.90 cm for males and ≥0.85 cm for females) 
[25]. There were no differences in the L-R ratio in participants classified as healthy 
weight versus overweight using BMI and in those with increased WC or waist: hip 
ratios in comparison to values within recommended references ranges (data not 
shown) [25 26].  
 
Correlation analyses between the L-R ratio, zonulin concentrations and body 
composition measures are displayed in Table 3. No associations were observed 
between small IP (L-R ratio) and body composition measures. Due to the differences 
in body composition between male and female participants, data was split by gender 
and reanalyzed. Although the findings were not statistically significant, the L-R ratio 
displayed a strong positive correlation with total body fat (r 0.566, p 0.055) and trunk 
fat (r 0.552, p 0.063) in male participants that was nearing statistical significance. No 
other significant correlations or trends were observed between body composition 
measures and the L-R ratio.  
 















There were no differences in zonulin concentrations in participants according to BMI, 
WC or waist: hip ratios classifications. No associations were observed between 
zonulin concentrations and body composition measures when explored in all 
participants (Table 4). However, zonulin concentrations displayed a statistically 
significant and moderate positive correlation with WC (r 0.437, p 0.042) and a 
moderate positive correlation that was nearing statistical significance with VAT (r 
0.418, p 0.053) in female participants. Furthermore, zonulin concentrations in female 
participants displayed a moderate positive correlation with BMI (r 0.368, p 0.092), 
whole body fat (r 0.391, p 0.072) and trunk fat (r 0.382, p 0.079), but findings were 
not statistically significant. Due to these findings, the association between zonulin, 
hs-CRP and LPS concentrations was explored in female participants. Zonulin 
concentrations displayed a strong positive correlation with hs-CRP concentrations (r 
0.571, p 0.005), with no correlation observed with LPS concentrations (r 0.131, p 
0.669). There were no associations between zonulin concentrations and body 




In this study, the associations between small IP (L-R ratio), zonulin concentrations 
and body composition measures were explored in healthy adult participants. No 
significant association was observed between the L-R ratio and zonulin 
concentrations, both used as measures of small IP in the literature. The L-R ratio 
displayed a positive association with LPS concentrations but no significant 














concentrations. Conversely, zonulin concentrations displayed a positive association 
with WC and hs-CRP concentrations in female participants, with no association 
observed with LPS concentrations. These findings do not support the study 
hypothesis but should be interpreted with consideration of the sample size and study 
limitations.   
 
4.1 Intestinal permeability and zonulin measurements  
 
Increasingly, zonulin concentrations are being used to measure small IP in lieu of the 
more arduous, but comprehensively researched, differential sugar-absorption test 
[14 15]. To our knowledge, the correlation between small IP and zonulin was first 
assessed in humans by Sapone and colleagues [13]. In this study, a statistically 
significant and moderate positive association (r 0.36, p 0.0004) was observed 
between the L-M ratio and zonulin concentrations in a subset of type I diabetic 
patients (n = 36) and their relatives (n = 56) [13].  
 
In our study, we did not observe a significant association between the L-R ratio, 
percentage recovery of lactulose and zonulin concentrations in healthy adult 
participants. This is in accordance with recent studies that have reported no 
significant associations between zonulin and small IP in a grouped analysis of 
patients with diarrhea-predominant irritable bowel syndrome, coeliac disease and 
healthy controls [33], frequent migraine sufferers [34], adults undertaking very 
intense sport activity (zonulin measured using stool assays) [35] and healthy 
participants in a crossover randomized controlled trial exploring the effects of inulin-














significant positive correlation between serum zonulin and urinary sucrose excretion 
in ulcerative colitis patients in remission, although this was similarly not observed 
between serum zonulin and the L-R ratio [37]. Nonetheless, there is limited research 
that has investigated the association between zonulin concentrations and the 
differential sugar-absorption test in healthy populations. This study adds to findings 
suggesting that the L-R ratio, a measure of small IP, may not be associated with 
serum zonulin concentrations in healthy populations. These findings are important in 
light of the increasing use of zonulin as a surrogate biomarker of IP in research 
studies involving healthy populations and warrants exploration on a larger scale [14 
15]. The view that zonulin concentrations alone may not be a reliable biomarker of IP 
is mirrored in a recent paper, which reinforces that more than 50 different proteins 
are involved in the regulation of intestinal tight junctions, highlighting the complex 
nature of tight junction regulation [16].  
 
4.2 Small intestinal permeability and body composition  
 
The association between the L-R ratio and body composition in healthy participants 
was explored in the present study. The initial intentions of the study were to 
investigate IP in participants of varying body compositions, however only 12 (35%) of 
the recruited participants were classified as either overweight or obese. Of these 
participants, five and three had an elevated WC and waist: hip ratio according to 
WHO classifications, respectively. Furthermore, in comparison to the National Health 
and Nutrition Examination Survey (NHANES) population-based dataset acquired 
with Hologic fan beam DXA scans across the United States from 1999 through to 














comparison to 25-year-old white males and white females [38]. Interpreted together 
with physical activity data and nutritional supplement usage, recruited participants 
overall had healthy body compositions, were exceeding recommended weekly 
physical activity targets and may have been more health conscious [39].  
 
The relationship between IP and body composition in healthy adults has not been 
researched extensively. In past studies, BMI was not found to correlate with 
measurements of IP [6-8], which is consistent with the findings of the present study. 
Despite not being related to BMI, a study by Gummesson and colleagues found that 
the 6-12 hour sucralose-mannitol ratio, used to reflect colonic IP, displayed a positive 
association with WC, VAT and liver fat measured using computed tomography in 55 
healthy female participants [7]. No significant associations were observed between 
small IP and body composition measures in the present study, which may in part be 
due to small participant numbers, although total body fat and trunk fat displayed a 
positive association with the L-R ratio in male participants that was nearing statistical 
significance. The majority of studies exploring IP and body composition have been 
completed in healthy female participants [7 8], with limited studies completed solely 
in male participants. Furthermore, data relating to colonic permeability, whole-gut 
permeability and body composition measures are not explored in this paper. The 
relationship between segmental IP and body composition, in particular visceral fat, 
needs to be measured in a larger powered study using gold standard methods, 
including a greater representation of varying body compositions in order to confirm or 















LPS concentrations displayed a positive correlation with the L-R ratio, suggesting 
that increases in small IP are associated with bacterial translocation in the small 
intestine in healthy populations. The findings from this study suggest that LPS 
concentrations in blood may be more reliable measures of increases in small IP in 
healthy populations, in comparison to zonulin concentrations. This needs to be 
further explored with consideration of limitations associated with the use of LPS 
concentrations as an indirect measure of bacterial translocation, including the short 
half-life of LPS in blood and variable detection rates [40]. 
 
Inflammation can be a consequence of increased IP and can similarly contribute to 
ongoing increases in IP [5]. In this study, hs-CRP concentrations did not correlate 
with the L-R ratio. However, only four participants were found to have elevated hs-
CRP concentrations above 3.0 mg/L, with a lack of heterogeneity in sample 
concentrations. Therefore, these findings may have been due to tests being 
completed in healthy participants who as a group were not considered to have 
increased inflammation. 
 
4.3 Zonulin and body composition  
 
Zonulin concentrations displayed a statistically significant positive correlation with 
WC and a positive correlation with VAT in female participants that was nearing 
significance. The inclusion of four females and only one male with a WC classified as 
“substantial risk” and the higher total body fat and trunk fat percentage observed in 
female participants may partly explain this finding. However, findings were not 














concentrations, waist: hip ratio [14] and WC [16 41] have been previously reported. 
However, none of these studies included direct measurements of IP, using zonulin 
as an independent biomarker of IP. Zonulin release is not restricted to enterocytes 
but also occurs in several tissues including, but not limited to, the liver and adipose 
tissue [16]. In this study, a positive correlation was also observed between zonulin 
concentrations and hs-CRP. Previous studies have proposed that zonulin can 
activate the complement system and that concentrations are associated with 
inflammatory markers [14 15 42]. 
 
It is plausible that serum zonulin concentrations in the present study were reflective 
of release from extra-intestinal tissues as opposed to providing an indication of small 
IP. Although this needs further exploration, it is possible that serum zonulin may be 
used as a risk marker of low-grade inflammation, visceral adiposity and/or metabolic 
syndrome in the future. The lack of an association between zonulin concentrations 
and body composition measures in males may have been due to the smaller number 
of males included in the study and the low abdominal fat content observed in these 
participants. Nonetheless, based on the results of the present study, zonulin 
concentrations may not reflect IP in healthy adults and levels may be elevated due to 
variations in abdominal adiposity and low-grade inflammation. Whether fecal zonulin 
concentrations are more reflective of small IP needs to be explored. 
 
4.4 Strengths and limitations  
The strengths of this study include the exploration of associations between small IP 
and body composition using a sensitive IP test, which has not been completed 














a study strength, with WC commonly used as a surrogate marker of abdominal 
adiposity in past studies. Furthermore, the comparison of the L-R ratio with zonulin 
concentrations has not been previously completed in healthy populations, despite 
zonulin being used as a biomarker of IP in research and selected clinical 
laboratories.  
  
The measurement of IP in a non-fasted state and deduction of baseline sugar 
concentrations from test concentrations may be viewed as a limitation as participants 
were not on standardized meal plans and due to the potential temporal variation in 
baseline sugar concentrations. However, baseline sugar concentrations in the 
present study were comparable to those detected in the urine samples of fasted 
participants [21], L-rhamnose and lactulose are not found abundantly in the diet and 
baseline concentrations of sugars can act as test confounders but are rarely tested 
and reported in IP studies. The measurement of zonulin in a non-fasted state may 
have similarly impacted serum concentrations. The small sample size is a limitation 
of the present study, which may have resulted in type II errors, therefore findings 
should be interpreted with caution. Although participants were excluded if they had 
GI conditions, diabetes or heart disease, a small number of participants had 
conditions associated with increased IP such as asthma and depression, 
nonetheless these participants were not found to have elevated L-R ratios or zonulin 
concentrations. Insulin resistance was not measured in the present study 
representing a limitation, with previous studies suggesting a possible link between 
increased IP, zonulin and insulin resistance [10 14]. An additional limitation relates to 
the completeness of urine collections. Approximately half of the participants reported 














complete versus incomplete collections, this represents a limitation of the study that 
may have impacted analysis and study findings. All studies employing urine 
collections in free-living populations should put methods in place to minimize the 
likelihood of incomplete collections occurring including frequent reminders and 
explanation of the importance of compliance for findings. Lastly, a number of recent 
studies have voiced significant concerns regarding the measurement of zonulin 
using commercial ELISA kits [43-45]. Findings suggest that currently available kits 
may not be specific to the detection of zonulin (prehaptoglobin-2) and that 
measurements are subject to high intra-participant variation [43-45]. These findings 
raise concerns regarding the use of presently available ELISA kits for the 
measurement of zonulin and question the interpretation of studies utilizing these 
analysis methods.  
 
In conclusion, this paper contributes important findings to the limited evidence base 
on the association between small IP, serum zonulin concentrations and body 
composition measures in healthy adults. LPS, but not zonulin concentrations, were 
related to small IP measurements. LPS may be a more reliable biomarker of small IP 
in this population. The use of serum zonulin as an independent biomarker of small IP 
in healthy populations should be carefully considered in future studies until more 
data is available. Conversely, zonulin concentrations were associated with hs-CRP, 
a marker of inflammation, and abdominal adiposity in healthy female participants. 
Further research studies are needed to explore the association between small IP, 
zonulin and body composition, including sex-specific relationships, using reliable 
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Table 1. Characteristics of healthy participants 
Variable  All 
participants  














Age, years 28.0 [8.0] 27.5 [7.0] 28.5 [10.0] 0.219 
Weight, kg 72.3 ± 17.4 87.5 ± 13.2 64.1 ± 13.5 <0.001 
Height, m 1.71 ± 0.11 1.82 ± 0.07 1.65 ± 0.07 <0.001 
BMI, [kg/m2] 23.7 [5.7] 25.8 [3.9] 21.2 [4.4] 0.006 
Waist circumference, cm 77.2 [16.9] 85.8 [7.1] 73.5 [8.0] 0.002 
Hip circumference, cm 100.9 ± 11.8 103.9 ± 5.6 99.3 ± 11.4 0.204 
Waist: hip ratio 0.79 ± 0.06 0.84 ± 0.05 0.77 ± 0.06 0.001 
Total body fat, %  27.6 ± 8.6 19.9 ± 5.3 31.7 ± 7.1 <0.001 
Trunk fat, % 23.5 [10.0] 18.4 [9.4] 25.6 [11.4] 0.006 
Visceral fat area, cm2 47.9 [41.1] 67.5 [25.5] 37.6 [32.8] 0.014 
Nutritional supplements     
No 15 (44.1) 5 (41.7) 10 (45.5) 1.000 
Yes  19 (55.9) 7 (58.3) 12 (54.5)  
Smoking 
No  
No, but have smoked in the last 
12 months 


















3-6 days a week 
1-2 days a week 





















































All participants, n=34; males, n=12; females, n=22. Data are analyzed by Independent-Samples t test 
for parametric variables, Mann-Whitney U test for non-parametric variables and Chi-Square Test for 
Independence for categorical variables. Data are presented as means ± standard deviation for 
parametric variables, medians [interquartile range] for nonparametric variables and numbers 
(percentage) for categorical variables. BMI, body mass index.  
a. p values for the differences between male and female participants, p values <0.05 are 
considered statistically significant. 
b. Physical activity was self-reported and assessed using questions from the Active Australia 
Survey [18]. Examples of moderate physical activity included walking, gentle swimming and social 


































L-rhamnose recovery, % 10.5 ± 4.4 9.5 ± 3.0 11.1 ± 5.0 0.297 
Lactulose recovery, %b 0.7 [0.5] 0.6 [0.6] 0.7 [0.4] 0.721 
Zonulin, ng/mL 45.7 ± 9.3 45.9 ± 6.9 45.5 ± 10.6 0.899 
hs-CRP, mg/L 0.32 [0.86] 0.17 [0.55] 0.55 [0.99] 0.217 
Endotoxins (LPS), EU/mLc 0.51 ± 0.15 0.53 ± 0.11 0.50 ± 0.18 0.683 
All participants, n=34; males, n=12; females, n=22. Data are analyzed by Independent-Samples t test 
for parametric variables and Mann-Whitney U test for non-parametric variables. Data presented as 
means ± standard deviation for parametric variables and medians [interquartile range] for 
nonparametric variables. EU, endotoxin units; hs-CRP, high-sensitivity C-reactive protein; L-R, 
lactulose/rhamnose; LPS, lipopolysaccharide. 
a. p values for the differences between male and female participants, p values <0.05 are 
considered statistically significant. 
b. n=33 (12 males, 21 females). 



















Table 3. Association between the lactulose-rhamnose ratio (measure of small intestinal permeability) and body composition measures in healthy participants  








L-R ratio All 
participants  
r 0.151 0.008 0.091 0.135 0.039 0.113 0.162 0.226 
p  0.400 0.967 0.615 0.453 0.828 0.531 0.367 0.206 
Males r 0.175 0.126 0.116 0.399 -0.119 0.566 0.552 0.420 
p  0.587 0.697 0.721 0.199 0.712 0.055 0.063 0.175 
Females r 0.038 -0.126 -0.004 0.018 -0.018 0.122 0.081 0.173 
p  0.869 0.586 0.987 0.938 0.939 0.600 0.728 0.454 
All participants, n=33; males, n=12; females, n=21. Data are analyzed by the Pearson Correlation test for parametric variables and the Spearman Rho test for non-parametric 

























Table 4. Association between zonulin and body composition measures in healthy participants 












r 0.173 -0.021 0.147 0.210 0.265 0.188 0.205 0.264 
p  0.327 0.905 0.408 0.233 0.129 0.288 0.246 0.131 
Males r -0.199 -0.169  -0.217 0.042 0.327 -0.202 -0.147 0.077 
p  0.535 0.600 0.498 0.897 0.299 0.529 0.649 0.812 
Females r 0.350 -0.025 0.368 0.437a 0.298 0.391 0.382 0.418 
p  0.111 0.912 0.092 0.042a 0.178 0.072 0.079 0.053 
All participants, n=34; Males, n=12; Females, n=22. Data are analyzed by the Pearson Correlation test for parametric variables and the Spearman Rho test for non-parametric 
variables. BMI, body mass index; VAT, visceral adipose tissue; WC, waist circumference; W:H ratio, waist: hip ratio.   

























  Anthropometric measures 
  DXA scan  
  Blood collection  
  Baseline 24-hour urine collection 
commenced 
Appointment 2: 
  Sugar solution consumed 
  Baseline 24-hour urine collection 
returned 
  Test 24-hour urine collection 
commenced  
Appointment 3: 
  Test 24-hour urine collection 
returned  
Figure 1. Overview of participant appointments   



























Figure 2. Study flow diagram  
Assessed for eligibility (n = 52) 
Excluded  (n = 17) 
   Not meeting inclusion criteria (n = 6) 
   Declined to participate (n = 11) 
Participants consented (n = 35) 
Participants included in analysis 
(n = 34) 
Excluded  (n = 1) 
   Did not return urine collection  
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